Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Curcumin for COVID-19: real-time meta analysis of 18 studies
Covid Analysis, June 28, 2022, DRAFT
https://c19curcumin.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dound (RCT) 33% 0.67 [0.54-0.82] 6 pt. scale 100 (n) 100 (n) CT​1 Improvement, RR [CI] Treatment Control Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Saber-Moghaddam 38% 0.62 [0.39-0.96] no recov. 11/21 17/20 Saber-Moghaddam 45% 0.55 [0.39-0.79] hosp. time 21 (n) 20 (n) Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Pawar (DB RCT) 60% 0.40 [0.09-1.75] death 2/15 5/15 Pawar (DB RCT) 91% 0.09 [0.01-1.56] death 0/25 5/25 Pawar (DB RCT) 67% 0.33 [0.01-7.87] death 0/30 1/30 Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Ahmadi (DB RCT) 21% 0.79 [0.48-1.31] recov. time 30 (n) 30 (n) Sankhe (RCT) 89% 0.11 [0.01-2.03] death 0/87 4/87 CT​1 Sankhe (RCT) 75% 0.25 [0.03-2.19] ventilation 1/87 4/87 CT​1 Sankhe (RCT) 46% 0.54 [0.35-0.76] no recov. 29/87 60/87 CT​1 Sankhe (RCT) 10% 0.90 [0.71-1.15] hosp. time 87 (n) 87 (n) CT​1 Majeed (DB RCT) 66% 0.34 [0.01-8.09] ventilation 0/45 1/47 CT​1 Majeed (DB RCT) 80% 0.20 [0.01-4.13] hosp. 0/45 2/47 CT​1 Majeed (DB RCT) 43% 0.57 [0.39-0.84] no recov. 45 (n) 47 (n) CT​1 Majeed (DB RCT) 25% 0.75 [0.56-1.01] no recov. 26/45 36/47 CT​1 Majeed (DB RCT) 6% 0.94 [0.80-1.10] viral time 45 (n) 47 (n) CT​1 Khan (RCT) 33% 0.67 [0.37-1.19] no recov. 10/25 15/25 CT​1 Khan (RCT) 39% 0.61 [0.43-0.87] no recov. 25 (n) 25 (n) CT​1 Khan (RCT) 50% 0.50 [0.30-0.84] viral+ 10/25 20/25 CT​1 Askari (DB RCT) -125% 2.25 [0.30-16.6] no recov. 3/8 1/6 Askari (DB RCT) -433% 5.33 [0.30-93.3] no recov. 2/6 0/7 Askari (DB RCT) 73% 0.27 [0.07-1.03] no recov. 2/12 8/13 Askari (DB RCT) 40% 0.60 [0.20-1.77] no recov. 3/10 7/14 Askari (DB RCT) 38% 0.62 [0.21-1.79] no recov. 4/13 4/8 Askari (DB RCT) -71% 1.71 [0.20-14.5] no recov. 2/7 1/6 Askari (DB RCT) 12% 0.88 [0.07-11.5] no recov. 1/8 1/7 Askari (DB RCT) 0% 1.00 [0.25-4.07] no recov. 3/13 3/13 Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Tahmasebi (DB RCT) 83% 0.17 [0.02-1.32] death 1/40 6/40 Tahmasebi (DB RCT) 67% 0.33 [0.01-7.72] death 0/20 1/20 Tahmasebi (DB RCT) 80% 0.20 [0.03-1.56] death 1/20 5/20 Hassania.. (DB RCT) -46% 1.46 [0.01-329] SpO2 imp. 20 (n) 20 (n) Asadirad (RCT) 26% 0.74 [0.26-2.12] death 5/27 6/24 Asadirad (RCT) 50% 0.50 [0.14-1.82] progression 3/30 6/30 Asadirad (RCT) 45% 0.55 [0.27-1.09] no recov. 8/27 13/24 Asadirad (RCT) 29% 0.71 [0.22-2.35] no recov. 4/27 5/24 Asadirad (RCT) 41% 0.59 [0.25-1.42] no recov. 6/27 9/24 Asadirad (RCT) 37% 0.63 [0.23-1.74] no recov. 5/27 7/24 Asadirad (RCT) 20% 0.80 [0.58-1.10] no recov. 18/27 20/24 Kartika 41% 0.59 [0.35-1.00] hosp. time 139 (n) 107 (n) Hartono (RCT) 53% 0.47 [0.32-0.68] viral+ 14/30 30/30 CT​1 Hartono (RCT) 75% 0.25 [0.09-0.66] viral+ 4/30 16/30 CT​1 Hartono (RCT) 67% 0.33 [0.01-7.87] viral+ 0/30 1/30 CT​1 Thomas (DB RCT) 44% 0.56 [0.34-0.91] improv. 74 (n) 73 (n) LONG COVID CT​1 Thomas (DB RCT) 82% 0.18 [0.07-0.47] improv. 74 (n) 73 (n) LONG COVID CT​1 Thomas (DB RCT) 64% 0.36 [0.16-0.84] improv. 74 (n) 73 (n) LONG COVID CT​1 Sankhe (SB RCT) 86% 0.14 [0.01-2.71] death 0/60 3/60 CT​1 Sankhe (SB RCT) 86% 0.14 [0.01-2.71] ventilation 0/60 3/60 CT​1 Sankhe (SB RCT) 67% 0.33 [0.04-3.11] ICU 1/60 3/60 CT​1 Sankhe (SB RCT) 10% 0.90 [0.71-1.15] hosp. time 45 (n) 45 (n) CT​1 Sankhe (SB RCT) 17% 0.83 [0.63-1.10] hosp. time 15 (n) 15 (n) CT​1 Sankhe (SB RCT) 32% 0.68 [0.54-0.86] recov. time 45 (n) 45 (n) CT​1 Sankhe (SB RCT) 36% 0.64 [0.49-0.83] recov. time 45 (n) 45 (n) CT​1 Sankhe (SB RCT) 4% 0.96 [0.75-1.23] recov. time 15 (n) 15 (n) CT​1 Sankhe (SB RCT) -5% 1.05 [0.99-1.11] recov. time 15 (n) 15 (n) CT​1 Sankhe (SB RCT) 44% 0.56 [0.38-0.81] viral load 44 (n) 43 (n) CT​1 Hellou (DB RCT) 77% 0.23 [0.06-0.95] NEWS2 33 (n) 17 (n) CT​1 Hellou (DB RCT) 92% 0.08 [0.00-1.38] oxygen 0/33 4/17 CT​1 Hellou (DB RCT) 70% 0.30 [0.05-1.67] oxygen time 33 (n) 17 (n) CT​1 Hellou (DB RCT) 13% 0.87 [0.07-10.6] hosp. time 33 (n) 17 (n) CT​1 Hellou (DB RCT) 10% 0.90 [0.47-1.71] viral+ 14/33 8/17 CT​1 Shehab 42% 0.58 [0.14-2.32] severe case 2/32 24/221 curcumin COVID-19 outcomes c19curcumin.com Jun 2022 1 CT: study uses combined treatment Favors curcumin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit